Echo Therapeutics Announces Positive Clinical Trial Results of Symphony® tCGM System

In short

We’ve covered Echo Therapeutics before with their clever needle free transdermal glucose monitoring kit, named Symphony®, together with its Prelude® SkinPrep System for transdermal drug delivery. The company has today announced positive results from its clinical trial of the Symphony tCGM System in elective cardiac surgery patients. This study is the first of two studies Echo is conducting in critically ill patients, with results from the second study expected later this quarter.


Data from this study demonstrate that Symphony successfully and continuously monitored glucose levels in the cardiothoracic surgical intensive care unit at Tufts Medical Center in Boston, Massachusetts. Data analysis demonstrated that Symphony read glucose levels accurately, with a mean absolute relative difference (MARD), or error rate of 12.3%.

The full press release including details of the study can be found here.

Clinician comments

“Echo’s data are extremely exciting in light of anticipated recommendations regarding glucose monitoring accuracy performance. Symphony’s accuracy in this study strongly suggests that it is within the expected recommendation that accuracy for intermittent blood glucose measurements in critically ill patients should be less than 12.5% error,” said Stanley A. Nasraway, Jr., M.D., Director of Surgical Intensive Care Units at Tufts Medical Center and the Principal Investigator of the Tufts study. “Echo’s study has produced compelling clinical evidence that this continuous technology can be used for safely sustaining glucose levels within a target range in acutely ill patients. Given the ease of use of this system and the potential cost-savings to hospitals it is likely that Symphony would transition with critically ill patients from the Intensive Care Units to the hospital general floors where better glucose control through technology-assistance is desperately needed in a setting of fewer nursing resources.”

Source: Echo Therapeutics Inc, PR Newswire